REPATHA PUSHTRONEX Rx

Select the drug indication to add to your list

REPATHA PUSHTRONEX

Hyperlipoproteinemias
Only 4 drugs may be compared at once

Generic Name and Formulations:

Evolocumab 420mg/3.5mL; per system (on-body infusor with prefilled cartridge); soln for SC use; preservative-free.

Company:

Amgen, Inc.

Select therapeutic use:

Indications for REPATHA PUSHTRONEX:

Adjunct to diet, alone or in combination with other lipid-lowering therapies, in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]) to reduce LDL-C. Adjunct to diet and other LDL-lowering therapies, in patients with homozygous familial hypercholesterolemia (HoFH) requiring additional lowering of LDL-C. To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular (CV) disease.

Adult:

Give by SC inj into abdomen, thigh, or upper arm; rotate inj sites. Primary hyperlipidemia, HeFH or CV disease: 140mg every 2 weeks or 420mg once monthly. HoFH: (≥13yrs): 420mg once monthly; measure LDL-C levels 4–8 weeks after initiation. To administer 420mg dose: give over 9 mins by using the on-body infusor or as 3 inj consecutively within 30 mins using the prefilled syringe or autoinjector.

Children:

Primary hyperlipidemia or HeFH: not established. HoFH: <13yrs: not established.

Warnings/Precautions:

Do not inject into areas that are tender, bruised, red, or indurated. Discontinue if serious allergic reactions occur. Severe hepatic impairment. Pregnancy. Nursing mothers.

See Also:

REPATHA

Pharmacological Class:

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

Interactions:

Avoid co-administration with other injectable drugs at same inj site.

Adverse Reactions:

Nasopharyngitis, URTI, influenza, back pain, inj site reactions.

Generic Availability:

NO

How Supplied:

Single-use prefilled syringe—1; Single-use prefilled SureClick autoinjector—1, 2, 3; Single-use Pushtronex system—1